Capital Research Global Investors
CLBT icon

Capital Research Global Investors’s Cellebrite CLBT Stock Holding History

Capital Research Global Investors’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,405,172
Closed -$43.4M – 464
2025
Q4 		$43.4M Sell
2,405,172
-20,564
-0.8% -$369K 0.01% 355
2025
Q3 		$44.9M Buy
2,425,736
+721,154
+42% +$11.3M 0.01% 357
2025
Q2 		$27.3M Buy
1,704,582
+1,241,592
+268% +$22.1M 0.01% 379
2025
Q1 		$9M Buy
+462,990
New +$9.74M ﹤0.01% 425

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Capital Research Global Investors's CLBT Position: Q1 2026 in Review

Capital Research Global Investors sold out of Cellebrite (CLBT) in Q1 2026, closing a stake of 2,405,172 shares — an estimated $43.4M sold.

Capital Research Global Investors first reported a position in CLBT in Q1 2025 and held it in 4 quarters. The position peaked at $44.9M in Q3 2025. 221 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • Capital Research Global Investors reported no remaining Cellebrite position as of Q1 2026 after selling out during the quarter.
  • Capital Research Global Investors sold 2,405,172 Cellebrite shares in Q1 2026, an estimated $43.4M.
  • Capital Research Global Investors first reported a position in Cellebrite in Q1 2025 and held it in 4 quarters.
  • Capital Research Global Investors's Cellebrite position peaked at $44.9M in Q3 2025.
  • 221 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.